Search results

119 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Social care guidelines Remove Social care guidelines filter
NICE guidelines Remove NICE guidelines filter
Medicines practice guidelines Remove Medicines practice guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter

Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]

Proposed [GID-TA10691] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

Proposed [GID-TA10694] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

Proposed [GID-TA10698] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etranacogene dezaparvovec for treating haemophilia B [ID3812]

Proposed [GID-TA10699] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

Proposed [GID-TA10702] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eptinezumab for preventing migraine [ID3803]

Proposed [GID-TA10677] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gefapixant for treating refractory chronic cough [ID3789]

Proposed [GID-TA10678] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for general anaesthesia [ID3796]

Proposed [GID-TA10679] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

Proposed [GID-TA10680] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

Proposed [GID-TA10682] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

Proposed [GID-TA10684] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

Proposed [GID-TA10683] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]

Proposed [GID-TA10660] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]

Proposed [GID-TA10733] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Liposomal bupivacaine for treating postoperative pain [ID3799]

Proposed [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibalizumabtreating for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

Proposed [GID-TA10657] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Proposed [GID-TA10720] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

Proposed [GID-TA10605] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]

Proposed [GID-TA10781] Expected publication date: 22 September 2021

Type

Technology appraisal guidance

Status

Proposed

Filter (7 in use)

Type 1 selected

Status 1 selected

Last updated

Guidance programme 5 selected

119 results

Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]

Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

Etranacogene dezaparvovec for treating haemophilia B [ID3812]

Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

Eptinezumab for preventing migraine [ID3803]

Gefapixant for treating refractory chronic cough [ID3789]

Remimazolam for general anaesthesia [ID3796]

Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

Lumasiran for treating primary hyperoxaluria type 1 [ID3765]

Burosumab for treating X-linked hypophosphataemia in adults [ID3822]

Liposomal bupivacaine for treating postoperative pain [ID3799]

Ibalizumabtreating for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]